COMPARISON OF THE EFFECT OF SALAMEXTRACT (Syzygium polyanthum (Wight) Walp) ADMINISTRATION 200 mg AND 300 mg ON APOLIPOPROTEIN-B LEVELS IN DISLIPIDEMIC PATIENTS

Abstract

Background: Dyslipidemia is a risk factor for cardiovascular disease. Meanwhile hyper-Apolipoprotein-B is a major and independent risk factor for cardiovascular disease. Bay leaf extract is reported to be effective in reducing cholesterol and triglyceride levels, and is expected to reduce Apolipoprotein-B, but the therapeutic dose is not known with certainty. This study aims to compare the effectiveness of bay leaf extract at a dose of 200 mg and 300 mg against Apolipoprotein-B levels in dyslipidemic patients.

Methods: This research is an experimental study conducted on 30 people with dyslipidemia. Group A (n = 15) and group B (n = 15) were randomly selected in a double disguise, each receiving 200 mg and 300 mg bay leaf extract capsules for 30 days. Apolipoprotein-B levels were measured before and after treatment. Data analysis was performed with SPSS where p <0.05 was stated as significant Results: Apolipoprotein-B levels before drug administration were compared with after treatment. Examination was found to decrease in group A ((109.8 + 13.71 vs 101.47 + 17.54) ng / dL; p value = 0.001) and group B ((122.6 + 21.08 vs 108.6 + 19.06) ng / dL; p value = 0.001), statistically significant both in group A and group B. The decrease in Apolipoprotein-B levels in group II was greater than in group I, but it was not statistically significant ((14 vs 8.33) mg / dL; p value = 0.567).

Conclusion: Giving bay leaf extract (Syzygium polyanthum) 2x200mg and 2x300mg for 30 days decreased Apolipoprotein-B levels. The decrease in Apo-B levels was greater in 2x300mg extract compared to 2x200mg, but statistically the difference was not significant.